The most prevalent are confirmation of the PUFA-enriched phospholipid phenotype in other types of cancer displaying therapy-induced GPX4 dependence [9, 78], investigating if dietary aspects like PUFA consumption and antioxidant supplementation affect resistance development and pre-clinical testing of co-therapies against lipid remodeling to combat ATT resistance development and disease progression to currently lethal CRPC. Here, GPX4 is linked to cancer.